FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, [D.C. 20549
---------------	------------

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPR	OVAL
	OMB Number:	3235-0287
	den	
ı	hours nor resnance.	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* LIPTON KAREN SHOOS						2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]									of Reporting Pe cable) or		10% Ow	ner
	`	ERAPEUTICS,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/10/2015								Officer below)	pecify			
(Street) HAMPTON NJ 08827				- 4. I -	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
		Tak	ole I - Noi	n-Deri	vativ	e Se	curities	s Ac	quired,	Disp	osed o	f, or Be	neficial	ly Owned	l			
Date			Date	nsactior n/Day/Yo	Execution Day/Year) if any		cution Date,				ties Acquired (A) or d Of (D) (Instr. 3, 4 and		Benefici	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	Price	Transaci (Instr. 3	ion(s)			(111501.4)
Common	Stock			06/1	10/201	0/2015		A		6,500 A		(1)	21	1,833		D		
			Table II -						uired, D , option					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution if if any (Month/Day	Date,	Code (In		of E		6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	es ally g d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to	\$25.41	06/10/2015			A		10,300		(3)	0	6/10/2025	Common Stock	10,300	\$0	10,30	0	D	

Explanation of Responses:

- 1. On June 10, 2015, the Company awarded 6,500 shares of the Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan, subject to time-based forfeiture restrictions.
- 2. Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
- $3. \ Such \ option \ vests \ in \ four \ equal \ installments \ beginning \ September \ 10, \ 2015.$

/s/ Avery W. Catlin, attorney in fact for Karen L. Shoos

06/11/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.